The DREAM study (Durvalumab with First-Line Chemotherapy in Mesothelioma) investigated the combination of PD-L1 inhibitor durvalumab and first-line chemotherapy (cisplatin and pemetrexed), and has brought survival benefits to patients (Nowak et al., 2020). Here, CD274 is linked to mesothelioma.